These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1512 related articles for article (PubMed ID: 11076429)
1. Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy. Chiou TJ; Tzeng WF; Wang WS; Yen CC; Fan FS; Liu JH; Chen PM Zhonghua Yi Xue Za Zhi (Taipei); 2000 Oct; 63(10):729-36. PubMed ID: 11076429 [TBL] [Abstract][Full Text] [Related]
2. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy. Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047 [TBL] [Abstract][Full Text] [Related]
3. A comparison of oral ondansetron syrup or intravenous ondansetron loading dose regimens given in combination with dexamethasone for the prevention of nausea and emesis in pediatric and adolescent patients receiving moderately/highly emetogenic chemotherapy. White L; Daly SA; McKenna CJ; Zhestkova N; Leal C; Breatnach F; Smelhaus V; Hung IJ; Kowalczyk J; Ninane J; Mitchell T; Haigh C Pediatr Hematol Oncol; 2000 Sep; 17(6):445-55. PubMed ID: 10989464 [TBL] [Abstract][Full Text] [Related]
4. Double-blind comparative trial of oral ondansetron versus oral granisetron versus IV ondansetron in the prevention of nausea and vomiting associated with highly emetogenic preparative regimens prior to stem cell transplantation. Fox-Geiman MP; Fisher SG; Kiley K; Fletcher-Gonzalez D; Porter N; Stiff P Biol Blood Marrow Transplant; 2001; 7(11):596-603. PubMed ID: 11760147 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of oral granisetron versus oral prochlorperazine in preventing nausea and emesis in patients receiving moderately emetogenic chemotherapy. Burris H; Hesketh P; Cohn J; Moriconi W; Ryan T; Friedman C; Fitts D Cancer J Sci Am; 1996; 2(2):85-90. PubMed ID: 9166505 [TBL] [Abstract][Full Text] [Related]
6. [Comparative trial of oral granisetron and intravenous ondansetron in patients receiving chemotherapy for breast cancer. Study Group of Granisetron]. Mabro M; Granisétron PK Bull Cancer; 1999 Mar; 86(3):295-301. PubMed ID: 10210764 [TBL] [Abstract][Full Text] [Related]
7. A double-blind comparison of the efficacy of two dose regimens of oral granisetron in preventing acute emesis in patients receiving moderately emetogenic chemotherapy. Ettinger DS; Eisenberg PD; Fitts D; Friedman C; Wilson-Lynch K; Yocom K Cancer; 1996 Jul; 78(1):144-51. PubMed ID: 8646710 [TBL] [Abstract][Full Text] [Related]
8. Comparative study of low-dose oral granisetron plus dexamethasone and high-dose metoclopramide plus dexamethasone in prevention of nausea and vomiting induced by CHOP-therapy in young patients with non-Hodgkin's lymphoma. Numbenjapon T; Sriswasdi C; Mongkonsritragoon W; Leelasiri A; Prayoonwiwat W J Med Assoc Thai; 2002 Nov; 85(11):1156-63. PubMed ID: 12546311 [TBL] [Abstract][Full Text] [Related]
9. Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience. Sorbe BG Semin Oncol; 1994 Oct; 21(5 Suppl 9):20-6. PubMed ID: 9113123 [TBL] [Abstract][Full Text] [Related]
10. Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy. Arpornwirat W; Albert I; Hansen VL; Levin J; Bandekar RR; Grunberg SM Cancer; 2009 Dec; 115(24):5807-16. PubMed ID: 19834961 [TBL] [Abstract][Full Text] [Related]
11. Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study. Perez EA; Hesketh P; Sandbach J; Reeves J; Chawla S; Markman M; Hainsworth J; Bushnell W; Friedman C J Clin Oncol; 1998 Feb; 16(2):754-60. PubMed ID: 9469367 [TBL] [Abstract][Full Text] [Related]
12. Antiemetic efficacy of three serotonin antagonists during high-dose chemotherapy and autologous stem cell transplantation in malignant lymphoma. Slabý J; Trnený M; Procházka B; Klener P Neoplasma; 2000; 47(5):319-22. PubMed ID: 11130251 [TBL] [Abstract][Full Text] [Related]
13. Phase II trial of ramosetron plus dexamethasone in the prevention of cisplatin-induced nausea and vomiting. Voravud N; Sriuranpong V J Med Assoc Thai; 2005 Dec; 88(12):1790-6. PubMed ID: 16518975 [TBL] [Abstract][Full Text] [Related]
14. Granisetron vs ondansetron for prevention of nausea and vomiting in hematopoietic stem cell transplant patients: results of a prospective, double-blind, randomized trial. Walsh T; Morris AK; Holle LM; Callander N; Bradshaw P; Valley AW; Clark G; Freytes CO Bone Marrow Transplant; 2004 Dec; 34(11):963-8. PubMed ID: 15489869 [TBL] [Abstract][Full Text] [Related]
15. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Poli-Bigelli S; Rodrigues-Pereira J; Carides AD; Julie Ma G; Eldridge K; Hipple A; Evans JK; Horgan KJ; Lawson F; Cancer; 2003 Jun; 97(12):3090-8. PubMed ID: 12784346 [TBL] [Abstract][Full Text] [Related]
16. Ondansetron and dexamethasone versus standard combination antiemetic therapy. A randomized trial for the prevention of acute and delayed emesis induced by cyclophosphamide-doxorubicin chemotherapy and maintenance of antiemetic effect at subsequent courses. Campora E; Giudici S; Merlini L; Rubagotti A; Rosso R Am J Clin Oncol; 1994 Dec; 17(6):522-6. PubMed ID: 7977174 [TBL] [Abstract][Full Text] [Related]
18. Comparative crossover trial of two intravenous doses of granisetron (1 mg vs 3 mg) + dexamethasone in the prevention of acute cis-platinum-induced emesis. Martoni A; Piana E; Strocchi E; Angelelli B; Guaraldi M; Zamagni C; Camaggi CM; Pannuti F Anticancer Res; 1998; 18(4B):2799-803. PubMed ID: 9713464 [TBL] [Abstract][Full Text] [Related]
19. Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial. Mantovani G; Macciò A; Bianchi A; Curreli L; Ghiani M; Proto E; Santona MC Cancer; 1996 Mar; 77(5):941-8. PubMed ID: 8608488 [TBL] [Abstract][Full Text] [Related]
20. Intravenous ondansetron plus intravenous dexamethasone with different ondansetron dosing schedules during multiple cycles of cisplatin-based chemotherapy. Chen PT; Liaw CC Chang Gung Med J; 2008; 31(2):167-74. PubMed ID: 18567417 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]